Phase I-II Clinical Studies:

• Global development perspectives - EU/USA/JAPAN
• Phase I - complete range of full service clinical pharmacology studies conducted in own unit in  Neuss (100 beds) and in Moscow and Belgrade
   
• Phase IIa - Fast Proof of Concept: access to large patient pools (incl. treatment-naive patients) at our locations in highly populated areas
• Bridging strategies Japan - EU/US, Phase I studies in healthy Japanese volunteers in Germany
• Late clinical pharmacology studies in special patient populations like renal/hepatic impairment, PK in patients
• Access to large volunteer/patient pool   
• Phase IIb and III studies in Western / Eastern Europe and Asia 
• Highly experienced medical staff in clinical pharmacology & immunology
• Biomarker research & immune-monitoring: The FOCUS Immunology Laboratory in Heidelberg generates added value to immunology and biomarker projects. www.focus-biomarker.de

In Early Drug Development:

• Product Development Management packages: We support our clients from the “idea” up to clinical Proof of Concept – special service for biotech companies or pharma’s second line products. The outcome is a high quality early clinical development package for either out licensing or further development to Phase III. www.pharma-development.com
• Development of regulatory strategy and regulatory support by in-house regulatory affairs professionals
• Cooperation with external experts (toxicology, pharmacology, EMEA)
• Strategic product consultancy and development planning for new clinical entities and biological entities, herbal products, generics plus, drug combinations (FDC) and medical device products